HOME >> BIOLOGY >> NEWS
New Treatment Successful With Hepatitis C

SAN FRANCISCO, Calif. -- An inexpensive new treatment for hepatitis C, a disease that afflicts 1-2 percent of the population, is more effective than the standard therapy, according to a recent study.

The pilot study, recently completed at Penn State's Milton S. Hershey Medical Center, treated patients with amantadine, a drug that has been available in the United States since the 1960s. Thirty percent of the patients in the study responded to amantadine treatment.

Amantadine costs only $20 per month -- a tiny fraction of the cost of interferon, the conventional treatment for hepatitis C. Interferon costs approximately $500 per month, and must be administered for at least six months.

Jill P. Smith, M.D., associate professor of medicine at Hershey, discovered that amantadine is an effective alternative treatment for hepatitis C -- without the extensive side effects associated with interferon. Smith will present the results of her study on May 19 at San Francisco's Mosconi Convention Center as part of the annual meeting of the American Gastroenterological Association and the American Association for the Study of Liver Diseases.

Interferon's frequent side effects include a drop in white blood cell count and flu-like syndrome with aches, pains and fever. Hair loss, anemia, thyroid disease and severe depression occur less frequently.

Amantadine has fewer side effects, including: difficulty in concentration, constipation and rare cardiac symptoms in some elderly patients. Another drawback of interferon treatment is that only 50 percent of the patients respond to it, according to Smith. Half of those responders relapse after they stop the six months of therapy, dropping the effectiveness rate to approximately 25 percent.

The poor response, side effects and cost of interferon treatment prompted Smith to look for another drug.

Smith's study included 22 patients who were monitored over a four-year period.
'"/>

Contact: Gail Brown
gxg14@psu.edu
717-531-8604
Penn State
22-May-1998


Page: 1 2 3

Related biology news :

1. St. Petersburg/New Haven Partnership for HIV/AIDS Care, Treatment and Support launched
2. Treatment stimulates growth and regeneration of injured adult skeletal muscle
3. Treatment of lupus in mice may point the way to human treatment
4. Treatment in mice proves effective against Duchenne muscular dystrophy
5. Treatment protects mouse ovaries from radiation therapy
6. National Institute on Drug Abuse launches National Drug Addiction Treatment Clinical Trials Network
7. Treatment restores normal heart rhythm in patients
8. Researchers Develop New Treatment For Hepatitis B And C As Nation Anticipates Surge In Number Of Cases
9. Researchers: Exciting Discovery Might Improve Cancer Treatment
10. Coffee Without Addiction, Possible New Treatment For Osteoporosis, Wrinkle-Free Cotton, And More
11. Scientists Discover Molecular Trigger Of Mucus Production, Suggesting First Treatment For Deadly Bronchitis, Other Diseases

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Treatment Successful With Hepatitis

(Date:11/21/2014)... REDMOND, Wash. , Nov. 20, 2014 ... access for the Internet of Things (IoT), today announced ... position of chief operating officer. Previously a strategic advisor ... marketing, finance, and operations. Mr. Traynor is based out ... . He reports to Chris Muench , ...
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
(Date:11/11/2014)... , Nov. 11, 2014  Forensicon, Inc., a ... firm, is pleased to announce the promotion of ... Director of Digital Forensics. In Schiff,s new role as ... the team of digital forensics examiners and provide leadership ... Photo - http://photos.prnewswire.com/prnh/20141110/157719 ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
(Date:12/13/2014)... December 13, 2014 The “Global ... major market drivers, threats, opportunities, and challenges. , ... three major players, namely, Thermo Fisher Scientific, Inc. ... These players jointly accounted for approximately ~65% of ... , Full Copy for This Report @ ...
(Date:12/13/2014)... 13, 2014 QuickSTAT is making significant ... Cold Chain capabilities, and is delighted to announce the ... to serve Life Science clients in the region. , ... controlled-ambient warehouse, will provide 24/7 transportation and logistics services, ... drugs, patient-clinical specimens, API, following IATA rules and EU ...
(Date:12/13/2014)... Dec. 11, 2014 Research and Markets ... of the "Glucose Sensors: the Next Generation" ... http://photos.prnewswire.com/prnh/20130307/600769 The convergence ... is giving hope for a better future to ... that can measure glucose levels accurately and reliably ...
(Date:12/13/2014)... RARITAN, N.J. and SAN ANTONIO ... Development, LLC (Janssen) today announced the presentation of data ... the Phase 3 EPO-ANE-3010 study evaluating epoetin alfa plus ... treat anemia in patients with metastatic breast cancer receiving ... primary objective, which was to rule out a 15 ...
Breaking Biology Technology:Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12
Cached News: